Brief: Prothena Announces Phase 3 Affirm-Al Clinical Trial For Birtamimab In Patients With Al Amyloidosis Did Not Meet Primary Endpoint
23/05/2025 21:54
Prothena Corporation PLC PRTA.O: PROTHENA ANNOUNCES PHASE 3 AFFIRM-AL CLINICAL TRIAL FOR BIRTAMIMAB IN PATIENTS WITH AL AMYLOIDOSIS DID NOT MEET PRIMARY ENDPOINT PROTHENA CORPORATION PLC - TO DISCONTINUE BIRTAMIMAB DEVELOPMENT PROTHENA CORPORATION PLC - PHASE 3 AFFIRM-AL TRIAL DID NOT MEET PRIMARY ENDPOINT PROTHENA CORPORATION PLC - SECONDARY ENDPOINTS NOT MET IN AFFIRM-AL TRIAL PROTHENA CORPORATION PLC - BIRTAMIMAB GENERALLY SAFE AND WELL-TOLERATED PROTHENA CORPORATION PLC - BOARD TO DECREASE SPEND, EXPECTS WORKFORCE REDUCTION Source text: ID:nBw3582YBa Further company coverage: PRTA.O
Recent news on Prothena
See all newsProthena Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Prothena's Q2 net loss narrows on lower expenses
Brief: Prothena Q2 Net Income USD -18.583 Million
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena posts Q1 revenue surge fueled by $50 million Novo Nordisk milestone payment